Corvus Pharmaceuticals (CRVS) announced that the IND application submitted by its partner in China, Angel Pharmaceuticals, has been approved by the Center for Drug Evaluation, CDE, of the China National Medical Products Administration, NMPA, to initiate a Phase 1b/2 clinical trial of soquelitinib for the treatment of patients with moderate-to-severe atopic dermatitis in China. Corvus co-founded Angel Pharma to develop its pipeline in greater China. Angel Pharma licensed the rights from Corvus to develop, manufacture and commercialize soquelitinib in greater China and is responsible for all expenses related to its development in China.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CRVS:
- Corvus Pharmaceuticals Holds Annual Stockholders Meeting
- Corvus Pharmaceuticals Reports Promising Phase 1 Trial Results
- Corvus announces new interim data from Phase 1 trial of soquelitinib
- Corvus Pharmaceuticals price target lowered to $11 from $12 at Mizuho
- Biotech Alert: Searches spiking for these stocks today